These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34745934)

  • 1. A Nomogram to Predict Disease-Free Survival Following Neoadjuvant Chemotherapy for Triple Negative Breast Cancer.
    Zhu M; Liang C; Zhang F; Zhu L; Chen D
    Front Oncol; 2021; 11():690336. PubMed ID: 34745934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcome assessment for triple-negative breast cancer: a nomogram analysis based on integrated clinicopathological, sonographic, and mammographic characteristics.
    Sheng DL; Shen XG; Shi ZT; Chang C; Li JW
    Eur Radiol; 2022 Oct; 32(10):6575-6587. PubMed ID: 35759017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
    Chen L; Kong X; Huang S; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
    Front Immunol; 2022; 13():831848. PubMed ID: 35320931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualized model for predicting pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: A multicenter study.
    Qian B; Yang J; Zhou J; Hu L; Zhang S; Ren M; Qu X
    Front Endocrinol (Lausanne); 2022; 13():955250. PubMed ID: 36060977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
    Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
    Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A CT-based deep learning radiomics nomogram for predicting the response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A multicenter cohort study.
    Cui Y; Zhang J; Li Z; Wei K; Lei Y; Ren J; Wu L; Shi Z; Meng X; Yang X; Gao X
    EClinicalMedicine; 2022 Apr; 46():101348. PubMed ID: 35340629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the impact of residual tumors at different sites post-neoadjuvant chemotherapy on prognosis in breast cancer patients and development of a disease-free survival prediction model.
    Yang H; Ruan Y; Sun Y; Wang P; Qiao J; Wang C; Liu Z
    Ther Adv Med Oncol; 2024; 16():17588359241249578. PubMed ID: 38736552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a prognostic nomogram for patients with triple-negative breast cancer with histology of infiltrating duct carcinoma.
    Jing N; Ma MW; Gao XS; Liu JT; Gu XB; Zhang M; Zhao B; Wang Y; Wang XL; Jia HX
    Ann Transl Med; 2020 Nov; 8(21):1447. PubMed ID: 33313192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Marmé F; Solbach C; Michel L; Schneeweiss A; Blohmer JU; Huober J; Fasching PA; Jackisch C; Nekljudova V; Link T; Rhiem K; Rey J; Denkert C; Hanusch C; Tesch H; Lederer B; Loibl S; Untch M
    Eur J Cancer; 2021 Aug; 153():203-212. PubMed ID: 34186505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy.
    Chen L; Huang S; Liu Q; Kong X; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
    Front Immunol; 2022; 13():849468. PubMed ID: 35669769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of postoperative survival of triple-negative breast cancer based on nomogram model combined with expression of HIF-1α and c-myc.
    Cui J; Jiang H
    Medicine (Baltimore); 2019 Oct; 98(40):e17370. PubMed ID: 31577739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and external validation of a prognostic model for predicting disease-free survival and risk stratification in breast cancer patients treated with neoadjuvant chemotherapy.
    Lai J; Wang H; Peng J; Chen P; Pan Z
    Cancer Manag Res; 2018; 10():2347-2356. PubMed ID: 30122984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.
    Li Y; Chen Y; Zhao R; Ji Y; Li J; Zhang Y; Lu H
    Eur Radiol; 2022 Mar; 32(3):1676-1687. PubMed ID: 34767068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy.
    Xia B; Wang H; Wang Z; Qian Z; Xiao Q; Liu Y; Shao Z; Zhou S; Chai W; You C; Gu Y
    Front Genet; 2021; 12():783513. PubMed ID: 34868273
    [No Abstract]   [Full Text] [Related]  

  • 15. Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer.
    Yang Y; Wang Y; Deng H; Tan C; Li Q; He Z; Wei W; Zhou E; Liu Q; Liu J
    BMC Cancer; 2019 Jun; 19(1):541. PubMed ID: 31170946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a nomogram for predicting survival of breast cancer patients with neoadjuvant chemotherapy: a dynamic analysis for systemic inflammation response index.
    Huang W; Xiong Z; Zhong W; Zhang C; Feng J; Wang X
    Gland Surg; 2023 Nov; 12(11):1459-1474. PubMed ID: 38107499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a prognostic nomogram for 2018 FIGO stages IB1, IB2, and IIA1 cervical cancer: a large multicenter study.
    Chen X; Duan H; Liu P; Lin L; Ni Y; Li D; Dai E; Zhan X; Li P; Huo Z; Bin X; Lang J; Chen C
    Ann Transl Med; 2022 Jan; 10(2):121. PubMed ID: 35282114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases.
    Xia LY; Hu QL; Zhang J; Xu WY; Li XS
    World J Surg Oncol; 2020 Jun; 18(1):129. PubMed ID: 32539858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Omar M; Nuzzo PV; Ravera F; Bleve S; Fanelli GN; Zanettini C; Valencia I; Marchionni L
    J Transl Med; 2023 Nov; 21(1):811. PubMed ID: 37964363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Model of D2 Radical Gastrectomy Combined with Neoadjuvant Chemotherapy for Gastric Cancer.
    Wang G; Tan Y; Jiang Y; Liu J; Su Y; Sun Z; Liu B
    Risk Manag Healthc Policy; 2023; 16():1259-1271. PubMed ID: 37456825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.